These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551 [TBL] [Abstract][Full Text] [Related]
5. Zhou H; Lei M; Wang W; Guo M; Wang J; Zhang H; Qiao L; Feng H; Liu Z; Chen L; Hou J; Wang X; Gu C; Zhao B; Izumchenko E; Yang Y; Zhu Y Aging (Albany NY); 2020 Nov; 12(22):22949-22974. PubMed ID: 33203800 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors. Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497 [TBL] [Abstract][Full Text] [Related]
7. Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. Moriya S; Che XF; Komatsu S; Abe A; Kawaguchi T; Gotoh A; Inazu M; Tomoda A; Miyazawa K Int J Oncol; 2013 May; 42(5):1541-50. PubMed ID: 23546223 [TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718 [TBL] [Abstract][Full Text] [Related]
9. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Xiang RF; Wang Y; Zhang N; Xu WB; Cao Y; Tong J; Li JM; Wu YL; Yan H Cell Death Dis; 2017 May; 8(5):e2776. PubMed ID: 28492559 [TBL] [Abstract][Full Text] [Related]
10. Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells. Moriya S; Komatsu S; Yamasaki K; Kawai Y; Kokuba H; Hirota A; Che XF; Inazu M; Gotoh A; Hiramoto M; Miyazawa K Int J Oncol; 2015 Feb; 46(2):474-86. PubMed ID: 25422130 [TBL] [Abstract][Full Text] [Related]
11. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Chauhan D; Singh A; Brahmandam M; Podar K; Hideshima T; Richardson P; Munshi N; Palladino MA; Anderson KC Blood; 2008 Feb; 111(3):1654-64. PubMed ID: 18006697 [TBL] [Abstract][Full Text] [Related]
12. Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma. Rizk M; Rizq O; Oshima M; Nakajima-Takagi Y; Koide S; Saraya A; Isshiki Y; Chiba T; Yamazaki S; Ma A; Jin J; Iwama A; Mimura N Cancer Sci; 2019 Dec; 110(12):3695-3707. PubMed ID: 31571328 [TBL] [Abstract][Full Text] [Related]
13. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma. Kikuchi S; Suzuki R; Ohguchi H; Yoshida Y; Lu D; Cottini F; Jakubikova J; Bianchi G; Harada T; Gorgun G; Tai YT; Richardson PG; Hideshima T; Anderson KC Leukemia; 2015 Sep; 29(9):1918-27. PubMed ID: 25801913 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Hideshima T; Catley L; Raje N; Chauhan D; Podar K; Mitsiades C; Tai YT; Vallet S; Kiziltepe T; Ocio E; Ikeda H; Okawa Y; Hideshima H; Munshi NC; Yasui H; Richardson PG; Anderson KC Br J Haematol; 2007 Sep; 138(6):783-91. PubMed ID: 17760810 [TBL] [Abstract][Full Text] [Related]
15. Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. Suzuki R; Kikuchi S; Harada T; Mimura N; Minami J; Ohguchi H; Yoshida Y; Sagawa M; Gorgun G; Cirstea D; Cottini F; Jakubikova J; Tai YT; Chauhan D; Richardson PG; Munshi N; Ando K; Utsugi T; Hideshima T; Anderson KC PLoS One; 2015; 10(12):e0143847. PubMed ID: 26630652 [TBL] [Abstract][Full Text] [Related]
17. Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib. Nakamura S; Miki H; Kido S; Nakano A; Hiasa M; Oda A; Amou H; Watanabe K; Harada T; Fujii S; Takeuchi K; Kagawa K; Ozaki S; Matsumoto T; Abe M Int J Hematol; 2013 Jul; 98(1):66-73. PubMed ID: 23708974 [TBL] [Abstract][Full Text] [Related]
18. The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells. Nagai Y; Mimura N; Rizq O; Isshiki Y; Oshima M; Rizk M; Saraya A; Koide S; Nakajima-Takagi Y; Miyota M; Chiba T; Oshima-Hasegawa N; Muto T; Tsukamoto S; Mitsukawa S; Takeda Y; Ohwada C; Takeuchi M; Iseki T; Nakaseko C; Lennox W; Sheedy J; Weetall M; Yokote K; Iwama A; Sakaida E Sci Rep; 2021 Jan; 11(1):2074. PubMed ID: 33483574 [TBL] [Abstract][Full Text] [Related]
19. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma. Ri M Int J Hematol; 2016 Sep; 104(3):273-80. PubMed ID: 27169614 [TBL] [Abstract][Full Text] [Related]
20. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma. Abdel Malek MA; Jagannathan S; Malek E; Sayed DM; Elgammal SA; Abd El-Azeem HG; Thabet NM; Driscoll JJ Oncotarget; 2015 Feb; 6(5):3098-110. PubMed ID: 25605012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]